An observational study in Parkinson's Disease, sponsored by Escape Bio, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Escape Bio, Inc. · Observational
Increase awareness of the G2019S LRRK2 mutation in Parkinson's and no cost genetic testing program.
This program is intended to increase awareness of genetic Parkinson's, in particular the G2019S LRRK2 mutation, and provide no cost genetic testing to determine if they carry the G2019S LRRK2 mutation.
4,488 studies on the registry are indexed under Parkinson Disease; 1,083 are open to participants now.
This study's enrollment of 836 is above the median of 96 across 1,057 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Escape Bio, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
A clinical diagnosis of Parkinson's disease
Participants include those with a clinical diagnosis of Parkinson's, in particular those who have a first- or second-degree relative with Parkinson's, or who have young onset Parkinson's (age less than 50 at diagnosis) or are of Ashkenazi Jewish or North African Berber descent, or have a relative with a known genetic mutation in the LRRK2 gene, or who have a genetic mutation in the LRRK2 gene.
Inclusion Criteria:
Participant eligible for enrollment in the program must meet all of the following criteria:
Exclusion Criteria:
No cost genetic testing for G2019S LRRK2
Identify Parkinson's patients with the G2019S mutation in their LRRK2 gene
To identify Parkinson's patients with the G2019S mutation in their LRRK2 gene through whole exome sequencing in order to support the development of an oral precision medicine.
Time frame: 2 years
Understand the proportion of Parkinson's patients who have a G2019S LRRK2 mutation
To obtain information about the proportion of Parkinson's patients who have a G2019S LRRK2 mutation.
Time frame: 2 years
Increase awareness of the importance of genetic testing in Parkinson's disease
To increase healthcare provider and patient awareness of the importance of genetic testing in Parkinson's disease in order to be aware of potential eligibility for clinical studies of genetic targeted medicines.
Time frame: 2 years
Increase interest of healthcare providers and patients participation in clinical trials
To engage healthcare providers and patients' interest in participation in upcoming clinical studies.
Time frame: 2 years
Plan to share: No
This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Escape Bio, Inc.